• The INFINITI CYP4502C9-VKORC1 Assay is CE Marked.
  • The INFINITI CYP450 2C9-VKORC1 is designed to identify CYP450 2C9 and VKORC1 genetic variants.
  • The INFINITI CYP450 2C9-VKORC1 utilizes the CYP450 2C9-VKORC1 Intellipac, CYP450 2C9-VKORC1 Amplification Mix and the CYP450 2C9-VKORC1 BioFilmChip Microarray.
  • The INFINITI CYP450 2C9-VKORC1 Assay is automated by the INFINITI Analyzer.
Analytes Detected: 
  • 2C9 Variants:          *2, *3, *4, *5, *6, *11
  • VKORC1 Variants:   3673 (-1639G>A)7566 (2255C>T)    
  •                                    6009 (698C>T)8773 (358C>T)    
  •                                    6484 (1173C>T)
  •                                    9041 (3730G>A)    
  •                                    6853 (1542G>C)
  • Multiplexed determination of 13 genetic variants
  • Rapid turnaround time enhances workflow efficiency
  • Load & Go automated on the INFINITI/INFINITI PLUS Analyzer.
  • Replicate determinations on a single BioFilmChip Microarray ensures quality results.
Sample Type and Volume: 
  • Requires 50 ng DNA / reaction, extracted from human blood samples.
Clinical Relevance: 
  • CYP450 2C9 is a major isoform in the cytochrome P450 (CYP450) family of drug metabolizing proteins, with a major role in the oxidation of xenobiotic and endogenous compounds.
  • CYP2C9 accounts for nearly 18% of CYP450 proteins found in the liver, where a majority of drug and toxic substance metabolism occurs.
  • Vitamin K epoxide reductase complex subunit 1 (VKORC1) play a significant role in individuals with combined deficiency of vitamin K depending clotting factors.
Clinical Utility: 
  • The CYP450 2C9 protein functions in a vast variety of important drug reactions that play an integral part in the way the body deals with many situations during medical treatment.
  • Examples of this are warfarin therapy (common anti-coagulant used in surgery), tolbutamide administration (oral agent used in type II diabetes treatments), and non-steroidal anti-inflammatory drug use (commonly used in arthritis treatment as well as other cases that require anti-inflammatory and/or analgesic effects.
  • VKORC1 gene status accounts for up to 25% in variance of warfarin dosing from patient to patient.
  1. Wood, A. J. J. : Racial differences in the response to drugs--pointers to genetic differences. (Letter) New Eng. J. Med. 344: 1393-1396, 2001.

  2. Sullivan-Klose, T. H.; Ghanayem, B. I.; Bell, D. A.; Zhang, Z.-Y.; Kaminsky, L. S.; Shenfield, G. M.; Miners, J. O.; Birkett, D. J.; Goldstein, J. A. : The role of the CYP2C9-leu-359 allelic variant in the tolbutamide polymorphism. Pharacogenetics 6: 341-349, 1996.
  3. Kirchheiner, J.; Stormer, E.; Meisel, C.; Steinbach, N.; Roots, I.; Brockmoller, J. : Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites. Pharmacogenetics 13: 473-480, 2003.